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6/j.bThe treatment of low- and intermediate-grade subtypes of malignant lymphoma continues to evolve. Mantle
cell lymphoma (MCL) accounts for 6% of all non-Hodgkin lymphoma (NHL) and is generally considered
incurable. Although high response rates can be achieved with initial chemotherapy, median survival is only
3-4 years. Intensified consolidation with high-dose therapy (HDT) and autologous stem cell transplantation
(ASCT) has been reported to improve progression-free survival (PFS), but most patients eventually relapse.
Indolent lymphoma accounts for 35% of all NHL and is associated with a median survival of 9 years. Similar to
MCL, it is also generally considered incurable, and the PFS also appears to be improved following HDT/ASCT.
We initiated a pilot study to evaluate idiotype (Id) vaccination following HDT and ASCT for patients with
MCL, indolent, and transformed NHL to evaluate the ability of Id-keyhole limpet hemocyanin (KLH) to in-
duce immune responses, and to evaluate overall survival (OS) and PFS. We treated 15 patients: 8 with MCL,
4 with follicular lymphoma, 1 with small lymphocytic lymphoma, and 2 with transformed lymphoma. After
a median follow-up of approximately 6.3 years (range: 1-9), PFS and OS at 9.05 years from time of ASCT
are 59% and 52%, respectively.
Biol Blood Marrow Transplant 18: 257-264 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: Non-Hodgkin lymphoma, Autologous stem cell transplantation, Idiotype vaccination,
ImmunotherapyINTRODUCTION
The treatment of low- and intermediate-grade
subtypes of non-Hodgkin lymphomas (NHL) con-
tinues to evolve. The introduction of immunothera-
peutic strategies has become an attractive means of
treatment, particularly with the use of passive immu-
notherapy (eg, rituximab). High response rates can
be achieved with chemotherapy, monoclonal anti-
bodies, and radioimmunotherapy. However, progres-
sion of disease is frequent. Intensified consolidation
with high-dose therapy (HDT) and autologous stemores UCSD Cancer Center, Blood and Marrow
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bmt.2011.06.011cell transplantation (ASCT) has been reported to
improve progression-free survival (PFS), but most
patients ultimately relapse [1-4].
The use of idiotype (Id) immunization to develop
an anti-Id antibody immune response has been dem-
onstrated as a promising approach to the treatment
of B cell lymphomas, and could result in more durable
remissions and improved overall survival (OS) than
with standard chemoimmunotherapeutic options [5-7].
Immunoglobulin (Ig) molecules on the surface of
clonal B cells in NHL can be used as a tumor-specific
target for immunotherapy. A unique Ig receptor ex-
pressed on the malignant B cell surface contains a
specific antigen-recognition region, the Id, which
can be targeted as a strong antigen for the induction
of an anti-Id immune response. The coupling of
the Id protein to keyhole limpet hemocyanin (KLH)
and simultaneous local administration of granulocyte-
macrophage colony-stimulating factor (GM-CSF)
produces an augmented immune response targeted
at malignant B cells while sparing normal B cells
[5,8]. Studies in animals and humans have shown
the effectiveness of the immune system to target Id
and kill lymphoma cells [9-12]. Treatment with
monoclonal anti-Id antibodies can cause tumor257
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remissions [12,13].
Invariably, early clinical trials in patients with B
cell lymphomas have shown that Id vaccination is
effective in eliciting specific anti-Id responses, accom-
panied by clinical benefit [14,15]. Long-term follow-up
of these patients has shown improved clinical out-
comes with prolonged PFS and OS [5]. Recent trials
have evaluated the use of Id vaccination in patients
with follicular non-Hodgkin lymphoma (NHL[FL]).
Early trials showed tumor regression and durable ob-
jective responses to vaccination in pretreated patients
with relapsed/refractory NHL used as a single agent,
or following rituximab immunotherapy [16-19].
Prior studies have demonstrated a strong inverse
correlation between the presence of detectable malig-
nancy and the laboratory detection of a cellular or hu-
moral Id-specific immune response [5,20]. Enhanced
immune responsiveness to vaccination that was seen
in patients in complete remission (CR) at the time of
vaccination prompted the hypothesis that a vaccine
was most effective in patients with minimal or no
detectable residual disease. This suggested the
consideration of HDT followed by ASCT as a means
to achieve a maximal response to therapy while
providing an ideal opportunity to mount an effective
immune response via Id vaccination. Davis et al. [21]
demonstrated the feasibility of this concept in 12 pre-
treated patients with refractory or relapsed B cell lym-
phomas, producing prolonged remissions particularly
in patients with FL. The applicability of Id vaccination
after ASCT in other subtypes of B-cell lymphoma has
not yet been evaluated.
Mantle cell lymphoma (MCL) was originally de-
scribed more than 30 years ago but was finally ac-
cepted as a separate entity when it became evident
that the t(11;14)(q12;q32) translocation was consis-
tently present [22,23]. MCL accounts for 6% of all
NHL and is often indolent or moderately aggressive
at diagnosis, but with time the disease invariably
becomes clinically aggressive and chemotherapy
refractory. It has shown the worst long-term survival
among all B cell lymphoma subtypes, and is generally
thought to be incurable [24]. Although high response
rates can be achieved with initial chemotherapy for
MCL, median survival is only 3-4 years [25]. Data
of cohorts following HDT and ASCT suggest
a higher event-free survival (EFS) and OS compared
with historic controls [2,26-32]; however, no
randomized trial has reached conclusive results [2].
All data suggest that there is no disease-free plateau,
and therefore relapse is likely in most patients with
MCL. Data from the Nordic Lymphoma Group
MCL2 study and theM. D. Anderson Cancer Center,
however, have recently shown that intensified con-
solidation with HDT and ASCT could provide
long-term disease control in chemotherapy-na€ıvepatients in first CR [28,33]. Although recent data
has been promising, relapse rates after HDT and
ASCT remain high [26,28,33-36].
With this background, we initiated a pilot study
evaluating Id vaccination following HDT and ASCT
for patients with MCL, indolent NHL, and trans-
formed NHL (TL) to explore the feasibility and effi-
cacy of this post-ASCT immunotherapeutic strategy
to induce and maintain complete clinical or molecular
remissions.METHODS
Patient Population
Between April 2001 and September 2006, 32 pa-
tients with NHL were enrolled in a pilot study to eval-
uate the feasibility, safety, and potential efficacy of Id
immunization following HDT and ASCT. Eligible
patients were between the ages of 18 and 75, had a
Karnofsky Performance Status of $70%, and had
received any number of prior chemotherapy regimens.
Patients may not have undergone prior HDT and
ASCT. Histologic confirmation of lymphoma was re-
quired and included patients with small lymphocytic
lymphoma (SLL), follicular small cleaved cell, follicu-
lar mixed small and large cell, MCL, or TL. Patients
were required to have a left ventricular ejection frac-
tion .40%, diffusion lung capacity of carbon monox-
ide.40% of predicted, creatinine\1.8mg/dL, and be
a candidate for ASCT. Patients were excluded for
known central nervous system lymphoma or menin-
geal lymphomatosis, human immunodeficiency virus,
or chronic inflammatory disorders requiring the
continued use of glucocorticoids or other immunosup-
pressive medications. The population included 16 pa-
tients with FL, 10 with MCL, 3 with TL, 2 with SLL,
and 1 with marginal zone lymphoma (MZL). The
institutional review boards of the participating centers
approved the study. Written informed consent was
obtained from all participants before enrollment.Treatment Design
A lymph node biopsy, peripheral blood draw,
or bone marrow biopsy was performed on eligible
patients to provide material for the generation of
tumor-specific Id. Patients whose lymphoma cells
expressed surface Ig were then eligible to continue
on the study. All patients had measurable disease after
obtaining tissue for vaccine production. Following
tissue collection, patients proceeded to undergo a
standard cytoreductive chemotherapy regimen before
stem cell mobilization, and HDT followed by
ASCT. Cytoreductive chemotherapy was chosen
and administered at the discretion of the treating
physician, although fludarabine and rituximab were
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cellular and humoral immune systems, respectively.
Vaccination was initiated at least 3 months after trans-
plantation, and followed an immunization schedule as
outlined below. Patients have subsequently been fol-
lowed for clinical and radiographic signs of relapse.
Vaccine Production
Id was produced by a proprietary recombinant
technology from the tumor-specific Ig light and heavy
chain genes captured from each individual patient’s
lymphoma cells, as previously described [37]. These
genes were molecularly identified by polymerase chain
reaction (PCR) amplification and cloned into a dual
gene baculovirus expression vector [38] containing
IgG1 (heavy chain, Vh) and kappa or lambda (light
chain, VL) constant regions. Following identification
of the tumor derived Ig Vh and VL region sequences,
heavy and light chain coding products were cloned,
and the Ig was subsequently coupled to KLH using
glutaraldehyde [14].
Vaccine Administration
Patients received a monthly subcutaneous vaccina-
tion of Id-KLH together with 250 mg GM-CSF at a
minimum of 3 months following ASCT, and vaccina-
tion was repeated for 4 consecutive months. This was
followed by a final vaccination 2 months thereafter.
A total of 250 mg GM-CSF was administered alone
by daily injections for 3 days following each Id-KLH
vaccination to enhance the immunogenicity and anti-
tumor effects, consistent with previous studies to
enhance the efficacy of the vaccine [37,39].
Cellular and Humoral Response Evaluation
To evaluate the ability of Id-KLH/GM-CSF to in-
duce cellular and immune responses, peripheral blood
mononuclear cells were obtained and cultured with
KLH, autologous Id, or a control patient Id. The
blood samples were obtained before each vaccination
and at 4 weeks following the completion of therapy.
The frequency of CD41T cells that stain for cytoplas-
mic interferon (IFN)-g or tumor necrosis factor
(TNF)-a was determined. A positive T cell response
to KLH was indicated by a result above the mean
plus 3 standard deviations observed in the controls. A
positive T cell response to Id is indicated by a result
3-fold higher than that observed with the irrelevant
control Ig.
To evaluate humoral immune responses, serial di-
lutions of serum samples were added to wells contain-
ing Id Fab fragments, KLH-coated wells, Id-KLH, or
a sham control. The presence of bound antibody was
detected using a goat anti-human IgG horseradish
peroxidase-conjugated antibody preparation in a stan-
dard enzyme-linked immunosorbent assay. At anypoint measured, a positive response to KLH was indi-
cated by a result above the mean plus 3 standard devi-
ations observed in the controls. A positive result to
Id was indicated by a result 3-fold higher than that
observed with the irrelevant control Id.
Disease Evaluation
Patients underwent routine staging by clinical ex-
amination, bone marrow, and peripheral blood evalu-
ation, and computed tomography (CT) or magnetic
resonance image (MRI) evaluation, before induction
chemotherapy, before HDT/ASCT, and at 30 days
following ASCT. Repeat evaluations of disease status
were performed at 3, 6, 9, and 14 months post-
ASCT. All patients were monitored closely for toxicity
during the study period. For non-MCL patients,
molecular evaluation of the bone marrow/peripheral
blood using PCR for the t(14;18) were obtained pre-
ASCT. No patients were found to have this chromo-
somal abnormality.
Statistical Methods
The durations of PFS andOSwere calculated from
the date the patient underwent ASCT until the date of
disease progression (PFS) and the date of death from
any cause (OS), or last follow-up as appropriate. The
probabilities of these outcomes as a function of time
were determined by the Kaplan-Meier method.RESULTS
Patient Characteristics
From April 2001 to September 2006, of the 32 pa-
tients enrolled in this pilot study, 15 patients received
Id immunization following HDT and ASCT. All
patients received HDT with Carmustine, etoposide,
cytarabine, and melphalan (BEAM) except for 1 MCL
patient who received cyclophospohomide, etoposide,
and carmustine (CEB), and 1 TL patient who received
131I-tositumomab, cytarabine, and etoposide. Of the
17 patients who came off study before receiving im-
munization, 12 had FL. Of these FL patients, 3 with-
drew consent, 1 underwent allogeneic stem cell
transplantation, 1 had an inadequate stem cell collec-
tion, and 1 was excluded for chronic steroid use result-
ing from BCNU toxicity post-ASCT. Vaccines could
not be produced for 6 FL patients. Of the remaining
5 patients, vaccines could not be made for 1 patient
with TL, and 4 patients were ultimately not recom-
mended for ASCT. Fifteen patients received Id immu-
nization: 8 with MCL; 4 with FL; 1 with SLL; and
2 with TL (Table 1) The median number of prior reg-
imens for all patients was 2 (range: 1-5), and all but 1
patient demonstrated chemosensitivity before ASCT.
Following induction therapy, 5 patients proceeded to
Table 1. Patient Characteristics
Patient No. Age Sex Histology
No. of Prior
Regimens
Disease Response
Before ASCT
Time from ASCT to
Vaccination (Months)
1 63 M MCL 2 CR 6
2 61 M MCL 3 PR 3
3 56 M MCL 1 CR 6
4 62 M MCL 2 CR 4
5 60 M MCL 2 CR 3
6 52 M MCL 1 CR 4
7 66 M MCL 1 CR 3
8 50 M MCL 1 CR 7
9 54 M FL 5 PR 3
10 54 F FL 1 PR 4
11 54 F FL 3 PR 4
12 48 M FL 4 PR 3
13 51 M TL 5 PR 6
14 66 M TL 2 PR 3
15 27 M SLL 3 SD 5
ASCT indicates autologous stem cell transplant; MCL, mantle cell lymphoma; FL, follicular lymphoma; TL, transformed lymphoma; SLL, small lymphocytic
lymphoma; CR, complete response; PR, partial response; SD, stable disease.
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CR, and 4 in second CR. One patient proceeded after
first relapse. For MCL patients, the median number of
prior regimens was 2 (range: 1-5), including rituximab,
cyclophosphamide, doxorubicin, vincristine, and pred-
nisone (R-CHOP), and cyclophosphamide, vincris-
tine, doxorubicin, and dexamethasone (hyperCVAD)
with or without rituximab. Five of the 8 MCL patients
received hyperCVAD as treatment. FL patients had
previously received a variety of regimens, including:
fludarabine; cyclophosphamide, vincristine, and pred-
nisone (CVP); CHOP; rituximab alone or in combina-
tion; and 90Y-ibritumomab. No patient received
rituximab as part of a maintenance regimen, just before
or after transplantation, or for the purpose of graft
purging.
After ASCT and before immunization, all but 1
patient had stable disease, a PR, or a CR. Patients re-
ceived the first vaccination between 3 and 7 monthsTable 2. Clinical Responses
Patient Histology
Response
Prevaccine 1
Response
Prevaccine 4
Response
9 Month
1 MCL CR CR CR
2 MCL PR CR CR
3 MCL CR CR CR
4 MCL CRu CRu CRu
5 MCL CR CR CR
6 MCL CR CR PD
7 MCL CR CR CR
8 MCL CR CR CR
9 FL PR CRu CR
10 FL SD SD SD
11 FL CR CR CR
12 FL PD PD PD
13 TL SD SD SD
14 TL CR PD Off Stud
15 SLL CR CR CR
MCL indicates mantle cell lymphoma; FL, follicular lymphoma; TL, transformed
CRu, complete response unconfirmed; PR, partial response; SD, stable dise
MDS/AML, myelodysplastic syndrome with progression to acute myelogenouspost-ASCT. All but 1 patient completed the immuni-
zation schedule and received all 5 vaccinations. Patient
14 received only 2 vaccines because of evidence of pro-
gressive disease.Clinical Responses
The median follow-up after ASCT and Id vaccina-
tion is 6 years, ranging from 1 to 9 years. Of the 15
treated patients, 8 are alive and are in CR (Table 2).
Six patients died of progressive disease, and 1 FL pa-
tient died of myelodysplasia that progressed to acute
myeloid leukemia (AML) at 34 months post-ASCT
without evidence of lymphoma. All 8 patients with
MCL achieved CR following ASCT, and 5 have re-
mained in continued CR (CCR) between 76 and 108
months post-ASCT. Three patients withMCL patient
relapsed at 10, 13, and 47 months after ASCT. Of the
3 FL patients who achieved CR, 2 continue in CR atat
s
Response at
14 Months
Time Since
ASCT (Months) Status
CR 108 Alive—CR
PD 23 Expired—PD
CR 72 Expired—PD
CR 94 Alive—CR
CR 90 Alive—CR
Off study 20 Expired—PD
CR 76 Alive—CR
CR 79 Alive—CR
CR 34 Expired— MDS/AML
SD 106 Alive—CR
CR 80 Alive—CR
PD 22 Expired—PD
SD 91 Alive—CR
y — 6 Expired—PD
CR 26 Expired—PD
lymphoma; SLL, small lymphocytic lymphoma; CR, complete response;
ase; ASCT, autologous stem cell transplant; PD, progressive disease;
leukemia.
Figure 2. OS of patients who received idiotype vaccination after ASCT
for NHL.
Table 3. Immune Responses to Id Vaccination Post-ASCT
Humoral
Responsiveness
Cellular
Responsiveness
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achieved a CR post-ASCT, but had progressive disease
at month 45. That patient subsequently underwent al-
logeneic stem cell transplantation and has remained in
a CCR. With a median follow-up of 6.3 years (range:
1-9), the PFS and OS at 9.05 years from the time of
ASCTare 59% and 52%, respectively (Figures 1 and 2).
After a median follow-up of up to 6.3 years, PFS and
OS for MCL at 9.05 years from the time of ASCT
was 62.5% and 60%, respectively. No patient with
MCL showed disease progression after 4 years or
died after 6 years.
Toxicities
Id immunizations were well tolerated, with injec-
tion site reactions being the most commonly reported
adverse events. Grade 3 toxicities included leucopenia
in 1 patient, vitreous hemorrhage in 1 patient, liver
abscess in 1 patient secondary to biliary stent obstruc-
tion, infection in 1 patient, and syncope in 1 patient.
As stated previously, 1 patient developed a secondary
treatment-related AML. All of these toxicities were
thought to be transplant-related events, not likely
related to Id vaccination. No limiting, sustained, or
delayed toxicities were identified, and no adjust-
ments were made to the vaccine formulation because
of toxicity.
Immune Responses
Specific anti-Id and anti-KLH responses, both hu-
moral and cellular, were noted in the majority of
treated patients (Table 3). Anti-KLH and anti-Id hu-
moral responses were noted as early as after the second
vaccine, although the majority of responders were
noted to be after the third vaccine. The patients who
developed a cellular anti-KLH and anti-Id response
did so after the second vaccine, although it was noted
to have occurred after the first vaccine in 3 patients.
Of the 5 patients with MCL with a CCR, 3 developedFigure 1. PFS of patients who received idiotype vaccination after
ASCT for NHL.anti-KLH and anti-Id cellular responses, 1 developed
anti-Id cellular response only, and 1 was not tested.
The patient with MCL who relapsed after 47 months
also had both anti-Id and anti-KLH cellular responses.
Three of the 4 FL patients developed anti-KLH
humoral responses, and 2 developed anti-Id humoral re-
sponses.Of the3FLpatientswhoobtained adurableCR,
2 developed an anti-Id and anti-KLH cellular response,
and the thirdwas not tested. A lack of viable cells for eval-
uation upon shipment to a reference lab limited the eval-
uation of an immune response for several patients.DISCUSSION
This pilot study illustrates the use of Id vaccination
as a feasible immunotherapeutic intervention follow-
ing ASCT for NHL. Early and Id-specific immunePatient Histology Anti-KLH Anti-Id Anti-KLH Anti-Id
1 MCL + + + +
2 MCL 2 2 2 2
3 MCL + NSR + +
4 MCL + + + +
5 MCL 2 2 + +
6 MCL + + NT NT
7 MCL + 2 NT NT
8 MCL 2 NT 2 +
9 FL + + + +
10 FL + NSR + +
11 FL + + NT NT
12 FL 2 2 NT NT
13 TL + + 2 2
14 TL NT NT NT NT
15 SLL + 2 NT NT
Id indicates idiotype; ASCT, autologous stem cell transplantation; KLH,
keyhole limpet hemocyanin; MCL, mantle cell lymphoma; FL, follicular
lymphoma; TL, transformed lymphoma; SLL, small lymphocytic lym-
phoma; NSR, nonspecific response; NT, not tested.
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as treatment for both indolent and more aggressive
lymphomas. Durable clinical responses were seen
with this approach, even in this heavily pretreated pop-
ulation. The early appearance and durability of specific
immune responses may be attributable to the adminis-
tration of Id immunization during awindow of immune
reconstitution following HDT/ASCT. Early data on
tumor-specific Id vaccines for the treatment of NHL
suggest that its use would be most effective in patients
with minimal or no detectable residual disease [5]. The
use of HDT/ASCT provides an ideal opportunity to
note effective immune responses to a vaccine based on
the unique Ig protein expressed by tumor cells.
Our study confirms previous data from animal
models that establish the ability of the immune system
to reconstitute andmount robust immune responses as
early as 2 weeks after myeloablative therapy [40,41].
T cell reconstitution may depend on the maturation
of peripheral cells present in the graft during
the posttransplantation setting of minimal residual
disease. As demonstrated in murine studies, the
maturing T cells may be antigen driven and with the
added advantage of immune reconstitution posttrans-
plantation, a specific window may be created for the
induction of a vigorous Id-specific immune response
[42]. The use of HDT may lead to a depletion of
regulatory T cells. A loss of this population of T lym-
phocytes, crucial in the control of T cell-mediated
autoimmunity by suppressing the proliferation and
cytokine production of other T cells, could allow for
an even more robust immune response.
Clinical studies of the use of Id vaccine in NHL
have largely focused on its use in the pretransplantation
setting in FL [8,16,19,37,43,44]. Despite early
enthusiasm, 2 phase III studies showed no benefit of
Id vaccine after induction chemotherapy for FL.
These data have assuaged its use and halted further
production of the respective vaccines [37,45]. Recent
data on the use of rituximab in FL for in vivo purging
and maintenance may also potentially overshadow the
proposed benefit of Id vaccination [46]. These data
were not available before initiating this study, and ritux-
imab was not used in these manners.
The potential benefit of Id vaccination in MCL is
not well established. Early studies showed the safety
and feasibility of Id vaccination following chemother-
apy in patients with MCL [47,48]. Anti-Id immune
responses were observed, even after rituximab-based
chemotherapy, showing that severe B cell depletion
does not impair T cell priming in humans [49]. Our
preliminary data showed that early development of ro-
bust immune responses may translate into prolonged
posttransplantation disease-free survival (DFS) in
MCL [50].
HDT/ASCT has been shown to improve the clini-
cal outcomes inMCL, a disease in which chemotherapyalone is insufficient for cure [2,51-56]. The MCL2
Study showed encouraging results for the use of
intensive immunochemotherapy followed by ASCT,
with no relapses seen after 5 years [28]. Updated data
after a median follow-up of 5.6 years reported a 10-year
OS of 58%; however, late relapses were seen [57].
Few studies have evaluated the use of Id vaccina-
tion in the posttransplantation setting [21]. This
study provides follow-up after 9 years in patients
with NHL who underwent HDT/ASCT followed
by Id vaccination. The PFS and OS, 59% and 52%,
respectively, suggest the possibility of long-term dis-
ease control using this strategy. The 9-year PFS and
OS of MCL patients, 62.5% and 60%, respectively,
also support the notion of improved long-term out-
comes in a lymphoma historically associated with
a poor prognosis. Because late relapses are of concern
after transplantation for MCL, no patient showed
disease progression after 4 years or died after 6 years
in this study.
Long-term follow-up of this population shows
promising effects of Id vaccination in the posttrans-
plantation setting on PFS and OS. Of the 15 patients
treated, 8 (53%) have shown durable remissions, 5 of
which were seen in patients with MCL. Detailed anal-
ysis of this subset of MCL patients showed a group of
male patients, age 50-66, stage IV disease, Karnofsky
Performance Status .70%, and few or no medical
comorbidities. Induction regimens included either
hyperCVAD or CHOP, with or without rituximab.
Three of these patients underwent ASCT in first CR,
and 2 patients in second CR. The similarities among
these long-term survivors with MCL may provide
a specific subset of patients to target for successful Id
vaccination in the future.
This experience supports the concept of Id vacci-
nation in the post-ASCT setting as a safe, feasible,
and effective intervention in patients with NHL. Our
data suggests the idea that there is an immune compo-
nent that can be exploited in this setting, and this
strategy may extend to more aggressive lymphomas.
Id vaccination in patients with MCL who undergo
ASCT shows early promise of providing durable
remissions and prolonged OS. Further investigation
of the use of Id vaccination in the posttransplantation
setting for MCL is necessary on a larger scale to con-
firm these findings.
This study presents a form of immunotherapy that
shows favorable effects on long-term disease control
in a subset of patients withMCL.We hope that these re-
sults spur a renewed interest in continuing this approach.ACKNOWLEDGMENT
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